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Abstract 
 
The discovery of the blood-brain barrier has allowed several studies focused on its 
properties throughout the last decades. The available study methods are both expensive and  
time-consuming. We describe a new simplified method for isolation of primary cultures of 
human brain microvascular endothelial cells (HBMVEC). Human samples of temporal lobe, 
obtained as discarded tissue during operative treatment for epilepsy, were mechanically 
fragmented and filtered through adequate pore-size polyester meshes. Resulting microvessel 
fragments were placed on type-I collagen-coated flasks to allow HBMVEC to migrate from 
vessels and proliferate. Usually, it takes approximately 1 month until confluence. The resulting 
cultures are highly pure and comprise important barrier properties such as: specific endothelial 
cell markers (von Willebrand factor and glucose transporter-1), expression of tight and adherens 
junctions (zonula occludens-1 and β-catenin, respectively), vesicular transport machinery 
(caveolae, through the expression of caveolin-1), ABC transporters (P-glycoprotein), as well as 
high transendothelial electric resistance, characteristics that are maintained for two passages. 
Furthermore, we have successfully cryopreserved primary HBMVEC maintaining the expression 
of the previously mentioned proteins important to barrier properties. 
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Sumário 
 
A descoberta da barreira hemato-encefálica permitiu, ao longo das últimas décadas, 
diversos estudos sobre as suas propriedades. Os métodos de estudo disponíveis são dispensiosos 
e morosos. Descrevemos um método novo e simples de isolamento e cultura de células 
endoteliais de capilares do cérebro humano (HBMVEC). Amostras humanas obtidas do lobo 
temporal, retirados do tecido descartado durante tratamentos cirúrgicos para epilepsia, foram 
mecanicamente fragmentadas e filtradas através de membranas de polyester com poro de 
tamanho adequado. Os capilares resultantes foram colocados em frascos revestidos com 
colagénio do tipo I para permitir tanto a migração de HBMVEC a partir dos capilares como a sua 
proliferação. Por norma, as células ficam confluentes em aproximadamente 1 mês. As culturas 
resultantes apresentam um grau de pureza elevado e apresentam importantes propriedades de 
barreira tais como: marcadores específicos para células endoteliais (factor de von Willebrand e 
transportador da glucose-1), expressão de proteínas de junções justapostas e aderentes (zonula 
occludens-1 e β-catenina, respectivamente), proteínas designadas de caveolinas que são 
marcadores das cavéolas, invaginações responsáveis por sinalização intracelular e internalização 
de substâncias (caveolina-1), transportadores ABC (glicoproteina-P), assim como elevada 
resistência eléctrica endotelial, características que se mantêm durante duas passagens. 
Adicionalmente conseguimos com sucesso criopreservar HBMVEC de culturas primárias, 
mantendo a expressão das acima referidas proteínas, importantes para as propriedades de 
barreira. 
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Chapter 1 – Introduction
 
In 1885, Paul Ehrlich was the first to experimentally demonstrate 
blood-brain barrier (BBB). He observed that vital dyes injected into the circulatory system stain 
all organs of the mammalian body 
1906). About 30 years later, 
phenomenon by injecting trypan blue directly into the cerebrospinal fluid which stained all 
central nervous system (CNS) and none of the peripheral organs (Goldmann, 1913). 
illustration showed that endothelial tight junct
between the blood and the brain. This was achieved by injecting horseradish peroxidase  
intravascularly, showing diffusion between endothelial cells 
vessels, though it did not pass between 
Karnovsky, 1967) (Fig. 1.1). 
 
 
Fig. 1.1 – Injected horseradish peroxidase 
cells to brain parenchyma. Adapted from 
 
The BBB has numerous 
brain from extracellular environment; (3) ensure constant supply of nutrients by specific 
transport systems ; (4) guide the inflammatory cells to resp
(Petty and Lo, 2002; Lee et al.
Maintenance of homeostasis is achieved by regulating ion balance (Wolburg and 
Lippoldt, 2002; Hawkins and Davis, 2005; Persidsky
substances (Chaudhuri, 2000; Khan, 2005)
substances, variations in blood composition 
and Wolburg, 2000; Petty and Lo, 2002; Wolburg and Lippoldt
-Brain Barrier
 
except the brain and spinal cord (Ehrlich, 1885; Ehrlich, 
an Ehrlich’s student,Edwin Goldmann, 
ional complexes physically limit solute exchanges 
(EC) lining skele
EC in the cerebral microvasculature (Reese and 
 
diffuse through brain vasculature but does not pass 
Reese and Karnovsky (1967). 
functions: (1) maintain the CNS homeostasis; (2) protect the 
ond to changes of local environment  
, 2006; Persidsky et al., 2006). 
 et al., 2006) and the infl
. This is essential in protection against harmful 
and breakdown of concentration gradients (Kniesel 
, 2002). 
 
1 
the existence of the 
noticed the opposite 
Further 
tal and cardiac 
through endothelial 
ux/efflux of 
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The BBB is present in all brain regions, except in those regulating autonomic nervous 
system and endocrine glands of the body, where blood vessels permit diffusion of blood-borne 
molecules across the vessel wall (Ballabh et al., 2004). 
BBB’s specific structural and biochemical properties arise from existent layers between 
the blood and the brain and from interactions between a large variety of cell types (Khan, 2005; 
Hawkins et al., 2006) 
 
1. eurovascular unit 
 
In the developing brain, capillaries are differentiated and matured into the BBB (Lee et 
al., 2006). Only capillary vessels have complete BBB properties. The circumference of the 
capillary lumen enclosed by a single EC (Hawkins and Davis, 2005) is very important: as the 
vessel diameter increases, so does the vessel leakiness (Marchi et al., 2004). 
Although BBB permeability itself is controlled by the biochemical properties of brain 
microvascular endothelial cells (BMVEC) (Pardridge, 1999), brain microvascular biology results 
overall from interactions of these cells with the basement membrane and neighbouring glial cells 
(Kaur and Ling, 2008), such as microglia and astrocytes, as well as neurons and perivascular 
pericytes (Wolburg and Lippoldt, 2002; Zlokovic, 2008; Zozulya et al., 2008). Altogether these 
constitute the neurovascular unit (Persidsky et al., 2006; Choi and Kim, 2008) (Fig. 1.2), 
essential for both health and function of the CNS (Hawkins and Davis, 2005).  
 
1.1 Basement membrane 
 
The basement membrane, constituted by 3 apposed laminas, is an essential part of the 
BBB, connecting BMVEC with the surrounding brain resident cells (Persidsky et al., 2006; 
Weiss et al., 2009). It is composed of different extracellular matrix classes of molecules. These 
are structural proteins (collagen and elastin), specialized proteins (fibronectin and laminin) and 
proteoglycans (Adibhatla and Hatcher, 2008; Wolburg et al., 2009). Matrix adhesion receptors 
are expressed in the vascular cells, neurons and supporting glial cells. These receptors are 
essential for maintenance of the BBB, as the disruption of extracellular matrix is strongly 
associated with increased BBB permeability in pathological states. (Hawkins and Davis, 2005; 
Zlokovic, 2008). 
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Fig. 1.2 – Schematic overview of the interactions between 
astrocytes and endothelial cells that globally 
(2005). 
 
 
1.2 eurons 
 
Little is known about the developmental role that neurons have on the BBB phenotype. 
However there is some evidence that neurons can regulate the function of blood vessels in 
response to metabolic requirements by inducing expression of enzymes unique for BMVEC 
(Persidsky et al., 2006). Also, BMVEC and astrocytic processes are directly innervated by 
noradrenergic, serotonergic, cholinergic, and GABA
Davis, 2005). The mature endothelium has a reciprocal function 
microenvironment that enables proper neuronal activity (Choi and Kim, 2008).
 
1.3 Microglia 
 
Microglia play a very important role in immune responses of the CNS. These cells 
present themselves in two forms: resting and activated microglia. When resting, cells have small 
bodies and long, thin processes. Activated microglia surveys local microenvironment by shifting 
from long to short processes, assuming a phagocytic 
-Brain Barrier
basement membrane and, neurons, microglia, pericytes, 
constitute the neurovascular unit. Adapted 
-ergic neurons, among others (Hawkins and 
morphology (Zlokovic, 2008). Microglia 
 
3 
 
from Hawkins and Davis 
inducing a stable 
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changes the phenotype in response to homeostatic disturbance of the CNS. According with the 
macrophage population in other organs, these cells have diverse effector functions 
and Perry, 2009). As microglia are found in
with BMVEC may contribute to the BBB properties (Choi and Kim, 2008). Still, the exact
mechanisms on how this proceeds remains unkown
 
1.4 Pericytes 
 
Pericytes (also known as vascular smooth muscle cells, mural cells, or myofibroblasts) 
are important cellular constituents of the capillaries and post capillary venules 
2008), having a close physical association with the endothelium. They 
membrane with the EC  (Bagley 
al., 2006) (Fig. 1.3). The location of pericytes on the microvessel and the degree of coverage 
varies considerably between different microvessel
correlate with the degree of tightness of the interendothelial junctions (Lai and Kuo, 2005). The 
vascular pericyte synthesizes most elements of the 
proteoglycans. Pericyte synthesis and release of laminal proteins is thought to be a critical step in 
the differentiation of the BBB (Dore
 
 
Fig. 1.3 – Pericytes Pericytes have a close physical association with the endothelium, 
membrane with the endothelial cells (A) and 
and Elsevier (2009). 
 
 
 
an Model of the Blood-Brain Barrier
 perivascular space, it is though that their interactions 
. 
share the same 
et al., 2005) and cover 22% to 32% of the capillaries 
 types (Allt and Lawrenson, 2001), 
basement membrane including a number of 
-Duffy et al., 2006). 
in 
 cover up to 32% of the capillaries (B). Adapted from 
 
(Ransohoff 
 
(Dore-Duffy, 
basement 
(Kim et 
seeming to 
 
 sharing the basement 
(Zlokovic, 2008) 
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Proper association of pericytes with microvascular endothelia is essential to maintain 
structural support and junctional integrity (Lai and Kuo, 2005; Braun et al., 2007). Pericytes and 
endothelial cells share tight junctions (TJ), adhesion plaques (Allt and Lawrenson, 2001) and 
soluble factors (Bagley et al., 2005).  
The association of pericytes to blood vessels has been suggested to regulate EC 
proliferation, migration and differentiation (Persidsky et al., 2006). There is also evidence that 
pericytes can induce and up-regulate P-glycoprotein (P-gp) functional activity in these cells 
(Dohgu et al., 2005). Furthermore, interactions between pericytes and BMVEC are important for 
the remodelling and maintenance of the vascular system via the secretion of growth factors or 
modulation of the extracellular matrix (Allt and Lawrenson, 2001). There is evidence that 
pericytes are involved in the transport across the BBB, as well (Allt and Lawrenson, 2001). 
Pericytes make regulatory adjustments in response to stress stimuli, as during severe and 
prolonged O2 deprivation (Al Ahmad et al., 2009). 
 Pericytes show rich contents of α-smooth muscle actin (α-SMA) which is a characteristic 
of the vascular smooth muscle cell, suggesting a contractile ability of pericytes (Lai and Kuo, 
2005). The physical contacts of pericytes’ cellular processes over interendothelial junctions 
coupled with the α-SMA contents suggest the functional role of pericytes in controlling blood 
flow as well as regulating junctional permeability. Pericytes have been shown to migrate away 
from brain microvessels in rapid response to hypoxia and traumatic brain injury. Both of these 
conditions are associated with increased BBB permeability (Hawkins and Davis, 2005). The 
disruption of BBB caused by the detachment of pericytes, reinforces the idea of pericytes’ role in 
junctional permeability (Nishioku et al., 2009). 
  
1.5 Astrocytes 
 
Astrocytes are glial cells whose endfeet form a lacework of fine lamellae closely apposed 
to the outer surface of the BBB endothelium (Abbott, 2002) (Fig. 1.4). Through contact with 
their feet, astrocytes are capable of transdifferentiating non-neural EC into the brain type, 
endowing them with the BBB properties (Hayashi et al., 1997). Therefore, astrocytes and EC 
interactions influence each other’s structure. They induce and modulate the development of the 
BBB and BMVEC’s unique phenotype, enhancing TJ and reducing gap junctional area (Abbott 
et al., 2006). 
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Astrocytes could play a major role 
increase in BMVEC charge selectivity 
functions (Yamagata et al., 1997; Bernoud
neuronal function and the close proximity of neuronal cell bodies to brain capillaries suggests 
that interactions between astrocytes and BMVEC are essential for a functional neurovascular
unit (Persidsky et al., 2006).  
Fig. 1.4 – Astrocytes’s endfeet form a fine lamellae closely apposed to the outer surface of the capillary 
endothelium. Adapted from Best (1990).
 
In some areas of the CNS there is a blood
not contact with astrocytes. Thus
some BBB features, likely due to soluble factors acting from the glia limitans or the 
subarachnoid cerebrospinal fluid
restoration of barrier integrity in vivo
2004; Persidsky et al., 2006). Attempts to recover BBB properties in 
included co-culturing BMVEC with astrocytes and/or astrocyte
al., 2008). Astrocytes may therefore modulate the BBB phenotype without being directly 
involved in the physical BBB properties. The non
maintaining the barrier properties of H
upregulate the tight junctional proteins 
transendothelial permeability across the H
2008). 
an Model of the Blood-Brain Barrier
in promoting proteoglycan synthesis with a resultant 
and playing an important role in the induction of BBB 
 et al., 1998). Astrocytes are essential for proper 
 
–tissue barrier with an endothelium 
, the microvessels lacking astrocytic ensheathment exhibit 
 (Abbott, 2002). Subsequent studies also showed loss and 
 following a temporary focal loss of astrocytes (Willis
BMVEC
-conditioned medium (Colgan
-contact co-cultivation with astrocytes helps 
BMVEC by secreting factors into the medium 
zonula occludens (ZO)-1 and occludin, and reduc
BMVEC (Siddharthan et al., 2007; 
 
 
 
that does 
still 
 et al., 
 cultures have 
 et 
in 
that 
e  the 
Colgan et al., 
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1.6 Endothelial cells 
 
EC were demonstrated to 
that horseradish peroxidase could not pass the endothelial layer from either direction, and that 
brain capillaries from amphib
movement of ions, despite the absence of surrounding astrocytes (Hawkins
now accepted that the cerebral endothelium forms the anatomic basis of the BBB in higher 
animals (Hawkins et al., 2006) and that 
(Khan, 2005). 
BMVEC interact intimately with other brain cells of the neurovascular unit, and hence 
can act as mediators between blood and brain (Calabria and Shusta, 200
regulate the selective transport and metabolism of substances from blood to brain as well as in 
the opposite direction from the parenchyma ba
The BMVEC barrier line is the most critica
brain (Ueno, 2007). Communication between 
the barrier functions consequently resulting in maintenance and elaboration of proper brain 
homeostasis (Choi and Kim, 2008).
 
Fig. 1.5 – Brain microvascular endothelial cells
leucocytes, such as monocytes and lymphocytes, and 
the neurovascular unit, such as neurons, astrocytes, microglia and peicytes, 
blood and brain. Adapted from Francis 
-Brain Barrier
be the responsible for BBB impermeability 
ians have high electric impedance, indicative of restriction to the 
he capillaries make up the primary part of the BBB 
ck to the systemic circulation 
l for preventing toxic substances from entering the 
EC and other surrounding cells 
 
 establish the contour of blood vessels with erythrocytes and 
interact intimately with the basement membrane and
hence operating 
et al (2003). 
 
7 
as it was observed 
 et al., 2006). It is 
8) (Fig. 1.5). They 
(Zheng et al., 2003). 
(Fig. 1.6) enhances 
 
 cells of 
as mediators between 
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The BMVEC lining the cerebral capillaries differ fundamentally from other vascular 
endothelia in their capacity to regulate the passage of molecules and cells to and from the neural 
parenchyma (Ge et al., 2005; Weksler
50–100 times tighter than peripheral microvessels as a result of special properties that cause 
severe restriction of the paracellular pathway for diffusion of hydrophilic solutes (Abbott, 2002).
 
Fig. 1.6 – Interaction between endothelial cells and other neighbouring cells enhance the barrier functions
from Zlokovic (2008). 
 
BMVEC lining the vascular wall have narrow junctional complexes that eliminate gaps 
or spaces between cells and prevent 
parenchymal space (Zlokovic, 2008; Weiss
thickness with no fenestrate, low pinocytotic activity and a continuous 
(Chaudhuri, 2000; de Boer and Gaillard, 2006). In addition, the BMVEC have a negative surface 
charge that repulses negatively charged compounds (de Boer and Gaillard, 2006). 
greater number and volume of mitochondria compared with endothelium in other organs
enhances the energy potential (Persidsky
compounds and various selective transport systems 
other compounds into and out of the brain (de Boer and Gaillard, 2006)
The BBB is more than an impermeable wall. It has 
transport systems that facilitate the uptake of important nutrients and hormones, and active 
pumps that help to regulate the concentrations of ions and metabolites in 
2003; Weksler et al., 2005; Zlokovic, 2008)
BMVEC are able to efficiently supply the brain with the metabolites required while contributing 
an Model of the Blood-Brain Barrier
 et al., 2005). The capillary endothelium in the brain is 
any free diffusion of blood-borne substances into the brain 
 et al., 2009). The EC cytoplasm has uniform 
basement membrane
 et al., 2006), and enable enzymes to break down 
allowing  active transport 
.  
a unique pattern of receptors,
the brain 
 that are schematically represented in Figure 1.7
 
 
 
 
. Adapted 
 
They have a 
, which 
of nutrients and 
 specific 
(Zheng et al., 
. The 
Establishment and Characterization of a Human Model of the Blood
 
 
to the maintenance of the brain's ion
of potentially harmful hydrophobic compounds
 
Fig.1.7 – Endothelial cells comprise a large variety of specific transporters
transporter-1 (GLUT-1), insulin receptor and 
(MRP) and P-glycoprotein (P-gp) which  regulate 
xenobiotics. For simplicity, other transporters and receptors are not represented, nor is depicted their differential 
expression in the luminal or abluminal membrane
 
The cerebral microvasculature lining is characterized by the presence of an elaborated 
junctional complex that includes mainly TJ and adherens junctions (AJ) proteins (Hawkins and 
Davis, 2005). Gap junctions have also been identified at the BBB, but their role in the barrier 
function is not clear (Zlokovic, 2008)
 
1.6.1 Tight junctions 
 
TJ are the main structures responsible for the barrier properties. These are elaborate
structures located on the apical region of 
regulates lateral diffusion between the apical and basolateral plasma membrane d
enables asymmetric distribution of membrane constituents and as a limit to paracellular 
permeability (Ge et al., 2005; Hawkins and Davis, 2005; Hawkins and Egleton, 2006; Persidsky
et al., 2006). Studies using TJ from different tissues with v
transepithelial electrical resistances show a correlation between increased organization of 
cytoplasmic fibrils and decreased membrane permeability (Huber
-Brain Barrier
ic homeostasis and protecting the CNS from a large 
 (Betz, 1992; Choi and Kim, 2008).
 and receptors, such as the 
ABC transporters, as the multidrug resistance
brain concentrations of nutrients, hormones, ions, metabolites, and 
. Adapted from Zlokovic (2008). 
 
EC (Fig. 1.8). They function both as a seal that 
arying transendothelial and 
 et al., 2001).
 
9 
variety 
  
 
glucose 
-associated protein 
d 
omains, which 
 
 
Establishment and Characterization of a Hum
 
10 
 
Fig. 1.8 – Tight junctions are located on the apical region of endothelial cells. 
parallel, interconnected, transmembrane and cytoplasmatic strands of protein arranged as a series of multiple 
barriers. Based on Schmieder (2007). 
 
The BBB TJ of mamm
complexity found in the vasculature of the body (Kniesel and Wolburg, 2000). Structurally, TJ 
form an intricate complex of parallel, interconnected, transmembrane and cytoplasmatic strands 
of proteins arranged as a series of multiple barriers (Wolburg and Lippoldt, 2002). 
occludin, and junctional adhesion molecules (JAM) are integral membrane proteins interacting 
with those of neighbouring plasma membrane and form TJ barrier (Petty and Lo,
Cytoplasmic TJ accessory proteins 
et al., 2004). 
 
1.6.1.1 Claudins 
The claudins (with approximately 24 kDa) are the TJ molecules
task of establishing barrier properties. 
the four transmembrane domains of occludin, but do not contain any sequence homology to 
occludin (Wolburg and Lippoldt, 2002). Therefore, claudins and oc
by different aminoacids with similar conformation, without sharing genetic information.
They form dimers and bind homotypically to other claudin molecules in adjacent 
BMVEC (Huber et al., 2001; Petty and Lo, 2002).  These protei
an Model of the Blood-Brain Barrier
They form an intricate complex of 
alian species are characterized first of all by the highest 
such as ZO connect integral TJ to the actin cytoskeleton (Lee
 that
These proteins are integral membrane proteins that share 
cludins are proteins formed 
ns are believed to be responsible 
 
 
Claudin, 
 2002). 
 
 seem to fulfil the 
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for permeability restriction (Tsukita et al., 2001). Although overexpression of claudins can 
induce cell aggregation and formation of TJ-like structures (Yamamoto et al., 2008), occludin 
expression does not result in the TJ formation. Thus, it appears that claudins form the primary 
seal of the TJ, and occludin acts as an additional support structure (Persidsky et al., 2006).  
In mammalian BMVEC only claudin-1, claudin-3 and claudin-5 were detected so far. 
Interestingly, claudin-5 was shown to be expressed primarily in EC of blood vessels (Petty and 
Lo, 2002; Mahajan et al., 2008; Neuhaus et al., 2008). Additionally, a novel anti-claudin-3 
antibody was recognized in BMVEC TJ (Wolburg and Lippoldt, 2002). Claudin-1 and claudin-5 
are associated with maintenance of normal BBB function (Vorbrodt and Dobrogowska, 2003) 
and are suggested to be important in angiogenesis and in disease processes with increased vessel 
permeability (Wolburg and Lippoldt, 2002). 
 
1.6.1.2 Occludins 
Occludin – a transmembranous TJ protein of approximately 65 kDa – was the first and 
best-known tight junctional transmembrane molecule discovered (Furuse et al., 1993). It is 
highly expressed and consistently stains in a distinct, continuous pattern along the cell margins in 
the cerebral endothelium, whereas it is much more sparsely distributed in non-neural 
endothelium (Hawkins and Davis, 2005). It has been shown that high levels of occludin ensure 
decreased paracellular permeability (Huber et al., 2001) and high electrical resistance of the 
BMVEC monolayers (Persidsky et al., 2006), having therefore an active role in BBB function 
(Yamamoto et al., 2008). However, it must be seen more in a  regulatory context than as a major 
structural protein in the establishment of the barrier properties (Wolburg and Lippoldt, 2002). 
Results of several knockout and knockdown experiments indicate that occludin is not essential 
for the formation of TJ (Hawkins and Davis, 2005) and that normal expression and localization 
of other junctional proteins well compensate  occludin loss (Zlokovic, 2008). Recently, there has 
been evidence that occludin regulates epithelial cell differentiation (Zlokovic, 2008). 
A feature of occludin is a calcium-independent adhesiveness, which is mediated by the 
first extracellular loop of occludin and depends on the presence of ZO-1 and AJ components 
(Kniesel and Wolburg, 2000). The cytoplasmic C-terminal domain provides the connection of 
occludin with the cytoskeleton via accessory proteins ZO-1, ZO-2 and ZO-3 (Shimizu et al., 
2008). 
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1.6.1.3 Junctional adhesion molecules 
Adhesion molecules such as the JAM family and the newly discovered EC-selective 
adhesion molecule are localized at TJ as well. (Wolburg and Lippoldt, 2002). JAM are members 
of the immunoglobulin superfamily expressed in TJ of EC (Vorbrodt and Dobrogowska, 2003) 
and mediate homophilic and probably also heterophilic interactions in the tight junctional region 
(Wolburg and Lippoldt, 2002). 
The JAM family consists of JAM-1, JAM-2, and JAM-3. These are 40-kDa proteins, 
from the IgG superfamily (Persidsky et al., 2006; Bernacki et al., 2008) and are composed by a 
single membrane-spanning chain with a large extracellular domain (Hawkins and Davis, 2005). 
JAM-1 is involved in cell-to-cell adhesion organizing the tight junctional structure and in 
monocytes extravasation through interendothelial junctions in vivo and in vitro (Stamatovic et 
al., 2008). It is believed that JAM-1 takes part in the formation of TJ as an integral membrane 
protein together with occludin and claudins (Vorbrodt and Dobrogowska, 2003). JAM-2 is 
involved in lymphocyte transmigration and interacts with JAM-3. As for this one, is implicated 
in cell-cell adhesion and in leukocytes transmigration (Stamatovic et al., 2008). Both JAM-2 and 
JAM-3 are present in EC of different organs (Wolburg and Lippoldt, 2002; Hawkins and Davis, 
2005), whilst JAM-1 is strictly present in the human cerebral cortex (Bernacki et al., 2008). 
 
1.6.1.4 Zonula occludens 
 Submembranous TJ-associated proteins such as ZO proteins (ZO-1, ZO-2 and ZO-3) 
belong to the family of membrane-associated guanylate kinase proteins (Persidsky et al., 2006), 
which serve as recognition proteins for TJ placement and as a support structure for signal 
transduction proteins (Huber et al., 2001). 
Membrane-associated guanylate kinases share three defined core regions: a SRC 
homology 3 (SH3) domain, a guanylate kinase and a postsynaptic density-95, disc large, and 
zonula occludens-1 domain. The SRC homology 3 domain binds signalling proteins and 
cytoskeletal elements. Guanylate kinase catalyses the ATP-dependent transformation of GMP to 
GDP. As for the postsynaptic density-95, disc large, and zonula occludens-1 domain, it mediates 
specific binding to carboxy-terminal cytoplasmic ends of transmembrane proteins (Wolburg and 
Lippoldt, 2002). 
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ZO-1, the first TJ-associated protein identified and characterized, is a 220-kDa 
phosphoprotein mostly expressed in endothelial and epithelial cells that normally form the TJ 
assembly (Kniesel and Wolburg, 2000; Persidsky et al., 2006). Though it is also expressed in 
other cell types that do not form TJ, there is no TJ without ZO-1. ZO-1 molecules are located on 
the cytoplasmic side of the BMVEC plasma membranes delimiting the interendothelial cleft 
(Vorbrodt and Dobrogowska, 2003) and connecting transmembranous TJ proteins with the actin 
cytoskeleton. Loss or dissociation of ZO-1 from the junctional complexes is associated with 
increased barrier permeability (Choi and Kim, 2008). ZO-2, a 160-kDa phosphoprotein, has 
significant homology to ZO-1. It was thought that ZO-2 was restricted exclusively to the TJ 
region (Kniesel and Wolburg, 2000); however, it has also been found in non-TJ-containing 
tissues. Very much like ZO-1, ZO-2 binds to transmembranous proteins of the TJ and 
transcription factors, and it is localized in the nucleus during stress and proliferation (Persidsky 
et al., 2006). It is not only an extremely important structural protein, but also a nuclear factor 
influencing gene expression (Wolburg et al., 2009) and blocking cell cycle progression 
(Gonzalez-Mariscal et al., 2009). 
Initially simply known as a protein that co-precipitated with the ZO-1/ZO-2 complex, 
ZO-3 has a close homology to ZO-1 and ZO-2. There is evidence that ZO-3 binds occludin and 
ZO-1 directly, but not ZO-2 (Kniesel and Wolburg, 2000). 
The complex formed by ZO-1 protein together with its supplementary components, ZO-2 
and ZO-3, is considered to be involved in cadherin-based cell adhesion through their binding to 
α-catenin and to actin filaments. Binding of ZO proteins to actin suggests that one possible 
function of these molecules is to form a scaffold to link TJ to the cytoskeleton. Given the 
evidence of their presence in zonula adherens, these proteins may be involved in cell-to-cell 
signal transduction (Vorbrodt and Dobrogowska, 2003). 
 
1.6.2 Adherens junctions 
 
AJ are composed of transmembrane glycoproteins of the cadherin super family, which are 
Ca
2+
-dependent receptors that form homotypic adhesive complexes with neighbouring cells, 
giving place to a continuous belt – the adhesion belt (Petty and Lo, 2002) (Fig. 1.9). 
AJ mediate events such as the adhesion of BMVEC to each other, the contact inhibition 
during vascular growth and remodelling, the initiation of cell polarity, and the regulation of 
paracellular permeability (Hawkins and Davis, 2005). Cell-cell adhesion by linking actin 
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filaments (Cook et al., 2008) involves vascular endothelial (VE)
constituents of AJ (Perrière et al.
catenin proteins form complexes of central importance to the sorting and morphogenic processes 
of developing animal tissues and in maintaining the integrity and identity of adult tissues (Tao
al., 1996). 
 
Fig. 1.9 – Adherens junctions are composed of 
catenins, giving place to the adhesion belt.
 
1.6.2.1 Cadherins 
Calcium-dependent cell-cell adhesion is dependent on a family of transmembrane 
glycoproteins named cadherins (Navarro
transmembrane components of AJ (Vorbrodt and Dobrogowska, 2003). Disruption of the AJ by 
removal of extracellular Ca
2+
 leads to the opening of the TJ (Hirase
Cadherins present a certain degree of cell type specificity. 
(VE-cadherin), also known as cadherin
exclusively in cells of vascular epith
the nervous tissue, vascular smooth muscle cells, and myocytes (Navarro
VE-cadherin is an important determinant of microvascular integrity both 
vivo (Vorbrodt and Dobrogowska, 2003). It clusters at cell junctions an
in a calcium-dependent manner, inhibits cell proliferation, and decreases cell permeability and 
migration when over-expressed in various cell types (Cook
an Model of the Blood-Brain Barrier
-cadherin and catenins, 
, 2007). The cadherin family and their intracellularly associated 
transmembrane glycoproteins of the cadherin super family and by 
 Adapted from Hill (2008). 
 et al., 1998), which can also be defined as major 
 et al., 1997)
Vascular endothelial
-5, is an integral membrane glycoprotein expressed 
elial origin, whereas Neural-cadherin is expressed in
 et al.
d mediates cell adhesion 
 et al., 2008). 
 
 et 
 
. 
-cadherin 
 cells of 
, 1998). 
in vitro and in 
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All cadherins contain a plasma membrane-spanning domain and a cytoplasmic domain 
associated with other molecular components of the junctional complex, such as catenins 
(Vorbrodt and Dobrogowska, 2003). VE-cadherin’s expression at cell junctions, however, is 
independent of β-catenin binding, which appears to be required only for junction stabilization 
(Cook et al., 2008). 
 
1.6.2.2 Catenins 
Catenins were first characterized as linking the cytoplasmic domains of cadherin cell-cell 
adhesion molecules to the cortical actin cytoskeleton. Catenins’ major roles is to anchor the 
cadherin complex to the actin cytoskeleton but they also participate in cell and developmental 
signalling pathways (Stamatovic et al., 2008). 
There are four types of catenin proteins: α-, β-, δ- and γ-catenin. α- and β-catenin are 
located in interendothelial junctions of BBB-type brain capillaries and their expression is 
required for cadherins to work as adhesion molecules (Vorbrodt et al., 2009). δ-catenin has been 
implicated as a regulator of the NF-κB transcription factor (Perez-Moreno et al., 2006), while  
γ-catenin is closely related to β-catenin and can replace it in the cadherin–catenin complex 
(Vorbrodt and Dobrogowska, 2003). 
 β-catenin is essential in endothelial cells for normal vascular patterning. It is a structural 
protein that participates in cell-cell adhesion and is also involved in the Wingless signalling 
pathway and in gene expression (Cook et al., 2008; Vorbrodt et al., 2009), serving as a mediator 
in regulation of P-gp and other multidrug efflux transporters in brain vasculature (Lim et al., 
2008). In addition, β-catenin is linked to the cell membrane in a complex with VE-cadherin and 
platelet-endothelial cell adhesion molecule. This molecule mediates homophilic adhesion 
(Wolburg et al., 2009). Upon stimulation with growth factors this membrane-associated complex 
is dissociated, releasing another source of β-catenin for movement to the nucleus and 
transcription (Petty and Lo, 2002). It is possible that the up-regulation of β-catenin elicits the 
maintenance of TJ protein assembly and barrier function (Vorbrodt et al., 2009). 
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2. Pathways across blood-
 
Passage of molecules across the endothelial cells of the BBB can occur between adjacent 
cells (the paracellular pathway) or through the cells (the transcellular pathway) 
1999). In the endothelium, the relationship of pa
crucial importance for the regulation of overall transendothelial permeability (Wolburg
2009). When it comes to the paracellular passage, ions and solutes diffuse between adjacent cells 
according to their concentration gradient (Petty and Lo, 2002). As for the transcellular pathway 
(Fig. 1.10), it involves different mechanisms including passive diffusion of lipophilic 
compounds, receptor-mediated shuttling and transcytosis. 
oxygen, CO2 and ethanol (Abbott, 2002),
2003), whereas hydrophilic molecules, such as peptides and proteins, may enter the brain 
through specific transport mechanisms (
molecules do not cross the BBB (Scherrmann, 2002).
 
 
 
Fig. 1.10 – The transcellular pathway: passage of molecules across the endothelial cells of the 
(BBB) can occur through different 
receptor-mediated shuttling. Polar molecules do not cross the 
 
An elaborate system of transport proteins
(GLUT-1) and ATP-binding cassette (
expressed on the luminal and abluminal 
   
an Model of the Blood-Brain Barrier
brain barrier 
racellular and transcellular permeability is of 
Small lipophilic molecules, 
 can pass the BBB freely by diffusion 
Norsted et al., 2008). Polar and lipid
 
mechanisms such as passive diffusion of lipophilic compounds or 
BBB. Adapted from Abbott et al.
, as caveolin-1, glucose transporter
ABC) transporters among others 
EC membranes (Hawkins et al., 2002)
 
(Pardridge, 
 et al., 
 
such as 
(Zheng et al., 
-insoluble 
 
blood-brain barrier 
 
 (2006). 
-1  
is asymmetrically 
. 
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2.1 Caveolae 
Caveolae have been suggested as sites of endothelial transcytosis, endocytosis, and signal 
transduction, and as docking sites for glycolipids and glycosylphosphatidylinositol-linked 
proteins (Simionescu et al., 2002; Wolburg et al., 2009). Caveolae are invaginations of the 
plasma membrane rich in the structural and functional coat protein caveolin (Fig. 1.11). Whilst 
caveolin is the distinct biochemical marker within caveolae domains, caveolae are also rich in 
cholesterol and sphingolipids (Smith and Gumbleton, 2006). In the BBB, the main caveolin 
marker proteins are caveolin-1 and -2. The presence of both on brain microvessels was 
demonstrated for BMVEC of rats, rhesus monkeys, porcine and of normal human samples 
(Virgintino et al., 2002). Caveolin-1 is the major structural protein of caveolae and is involved in 
various aspects of vesicular trafficking and signal transduction pathways (Huber et al., 2001).  It 
has also been reported that both occludin and ZO-1 might be organized within TJ by association 
with caveolin-1 in detergent-insoluble glycolipid rafts (Smith and Gumbleton, 2006). Caveolin-1 
has been proposed to not be required for endocytosis but instead to stabilize endocytic raft 
domains decreasing endocytosis (Nabi and Le 2003).  
 
2.1 GLUT-1 
 GLUT-1 ensures nutrient delivery, supplying glucose for the brain (Persidsky et al., 
2006), the main energy source of the brain. The 55-kDa form of GLUT-1 is highly restricted to 
the capillary EC in the brain (Wolburg et al., 2009). The density of GLUT-1 at the abluminal 
membrane is higher than at the luminal. The asymmetrical distribution provides homeostatic 
control for glucose influx into the brain by preventing glucose accumulation in the brain at levels 
higher than those in the blood (Zlokovic, 2008). Interestingly, GLUT-1 may also be present at 
peripheral nerve pericytes transporting D-glucose from the circulating blood into the brain and 
peripheral nervous parenchyma in cooperation with that on the EC (Shimizu et al., 2008). 
 
2.3 von Willebrand Factor 
BMVEC are usually characterized for staining for von Willebrand factor (vWF). Also 
known as factor VIII-related antigen, it is a carrier protein for coagulation factor VIII stored in 
large and microvessel endothelium. Although some people consider vWF the most reliable 
marker for EC, others showed loss of staining after passaging with trypsin (Craig et al., 1998). 
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Fig. 1.11 – Caveolin-1 is the major structural protein of caveolae and is involved in various aspects of vesicular 
trafficking and signal transduction pathways.
 
2.4 ABC transporters 
Efflux of molecules from the brain endothelium can be initiated at the luminal membrane, 
as in the case of the ABC transporters. 
resistance phenotype, together with the multidrug res
are responsible for the active extrusion of nonpolar molecules out of 
focus of research on drug delivery to the brain 
between P-gp and caveolin-1, as t
activity of P-gp (Demeule et al., 2000; Barakat
entry of blood-borne substances into the brain and facilitates their transport out of the brain 
parenchyma (Choi and Kim, 2008)
breast cancer resistance protein, mediate the efflux of anionic compounds (Zlokovic, 2008). 
These transporters have the potential to reduce penetration of many drugs into th
increase their efflux from the brain.
 
 
  
an Model of the Blood-Brain Barrier
 
 Adapted from Abbott et al. (2006). 
P-gp is a transporter for the acquisition of the multidrug 
istance-associated protein 
EC and are therefore the 
(Shimizu et al., 2008). There is an
he down-regulation of caveolin-1 enhances the transport 
 et al., 2007). P-gp in the endothelium prevents 
. The multidrug resistance-associated protein
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3. Methods to evaluate BBB characteristics 
 
BBB characteristics are often assessed by monitoring certain properties. There are 
various methods to study the properties of the BBB in vivo (Mano et al., 2002), ex-vivo (Ebert 
and Svendsen, 2005), in silico (Garg and Verma, 2006) and in vitro (Hawkins et al., 2006), 
giving valuable information on a large variety of matters.  
 
3.1 Study systems 
 
3.1.1 Studies in vivo 
 
In vivo studies provide the most reliable reference information for testing and validating 
other models. They take into account not only a section but the whole brain microenvironment. 
The most recent studies on BBB disorders include, for example, information on Parkinson’s 
disease with primates (Astradsson et al., 2009), and multiple sclerosis (Coisne et al., 2009) or 
cerebral ischemia (Abulrob et al., 2008) with mice. Nonetheless, they can be applied strictly to 
animals and require expensive equipment (Malina et al., 2009). 
 
3.1.2 Studies ex vivo 
 
Ex-vivo studies are performed on living tissue in an artificial environment outside the 
organism. These studies may also be performed on post-mortem tissues. This allows 
experimentation under highly controlled conditions impossible in the intact organism, for 
example in Alzheimer’s disease studies (Ebert and Svendsen, 2005). 
 
3.1.3 Studies in silico 
 
In silico prediction methods are cheaper and less limited than obtaining experimental data 
through other methods, and are very useful in permeability studies. However, these studies are 
performed strictly via computer simulation (Malina et al., 2009; Mensch et al., 2009). 
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3.1.4 Studies in vitro 
 
Even though in vitro models of the BBB continue to be labour-intensive and difficult to 
reproduce, they permit to mimic the BBB microenvironment while studying not only a larger 
range of properties and functions (Aschner et al., 2006), and to perform studies  in different 
animal species. Most reports fall upon brain tissue from rat (Perrière et al., 2007) and mouse 
(Coisne et al., 2005), as well as from feline (Fletcher et al., 2009), porcine (Zhang et al., 2006) 
and bovine (Zhang et al., 2009) models. However, the results obtained must take into account the 
differences between species. Furthermore, experiments with human tissue are extremely difficult 
and require methods both time-consuming and expensive (Hewett, 2009). Thus, cell lines 
became the most obvious alternative. 
 
3.1.4.1 Cell lines 
Establishment of a human model of the BBB has been proven difficult to achieve. To 
accomplish this, normal HBMVEC were transduced by lentiviral vectors incorporating human 
telomerase or SV40 T antigen, giving rise to cell lines. Human cell lines allow a faster and more 
frequent access to HBMVEC, as well as larger amount of cells per experience. These cells 
achieve confluence in a few days and maintain their phenotype and karyotype for several 
passages (Weksler et al., 2005). Whilst a range of immortalized BBB cell lines are commercially 
available, they commonly present leaky intercellular junctions and a poorly differentiated 
phenotype compared to their in vivo siblings, characteristics which limit their effective use as 
robust and predictive in vitro BBB models (Smith et al., 2007). 
 
3.1.4.2 Primary cultures 
Primary cell cultures of BMVEC, though technically challenging to isolate and maintain, 
represent the closest possible phenotype to the in vivo BBB cell providing a convenient model 
and the optimal choice for BBB research (Smith et al., 2007). Several attempts to develop in 
vitro models of the BBB have been previously reported, using BMVEC from different species 
(Zenker et al., 2003; Siddharthan et al., 2007). Although primary cultures of HBMVEC have 
been shown to retain some phenotypic characteristics of brain endothelium, many problems have 
been encountered. Some relate to the difficulty to obtain pure endothelial cultures, as the basal 
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membrane surrounding the microvascular endothelium also encloses pericytes that are difficult 
to remove from the endothelial fraction (Calabria et al., 2006). Therefore, these cells often 
contaminate BMVEC cultures. Another problem relates to loss of many of the functions 
observed in vivo, assigned to the removal of BMVEC from local brain microenvironment 
(Calabria et al., 2006). They rapidly lose their specific characteristics in culture (Nakagawa et 
al., 2009) undergoing dedifferentiation and senescence even upon limited passaging, thus 
hampering usefulness as in vitro models of the human BBB (Weksler et al., 2005). Therefore, 
data generated from in vitro systems have to be carefully interpreted since it is unclear to what 
extent the de-differentiation is occurring (Calabria and Shusta, 2008). 
 
3.1.4.3 Co-cultures 
Research on BBB functionality/recovery has been very much enhanced by the availability 
of in vitro BBB co-culture systems (Ramsauer et al., 2002; de Boer and Gaillard, 2006) 
(Fig.1.12). The discovery of cell-culture inserts with porous filter membranes allowed the use of 
BMVEC for permeability studies in vitro (Nakagawa et al., 2007). In addition, the use of such 
systems allows the study in detail of BBB related phenomena at the sub-cellular level in the 
absence of feedback systems from the rest of the body (Megard et al., 2002; de Boer and 
Gaillard, 2006). With co-cultures it has also been possible to evaluate effects on BMVEC under 
flow or shear stress, in the presence of other types of cells (Kim et al., 2006). There have been 
studies performed with co-cultures of BMVEC and astrocytes both from either mouse 
(Ghazanfari and Stewart, 2001) or rat (Perriere et al., 2007), as well as from bovine (Gaillard et 
al., 2001) and porcine (Jeliazkova-Mecheva and Bobilya, 2003) models. Up until now, studies 
with HBMVEC are performed by co-culturing these cells with non-human astrocytes 
(Santaguida et al., 2006). Most recently, there have also been studies with triple cultures of 
BMVEC, astrocytes and pericytes, though all extracted from rat brain (Nakagawa et al., 2009).  
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3.2 Function assessment 
 
3.2.1 TEER 
 
Transendothelial electrical resistance (TEER) is a useful 
and BMVEC barrier function (Calabria
measuring, including the epithelial 
(Fig. 1.13), in an EndOhm chamber, or even connected to 
continuously (Davidson et al., 2009; Malina
It has been difficult to reproduce in cultured cells the high electrical resistance normally 
found across BBB EC in situ (Santaguida
100 Ω.cm
2
 or lower (Calabria and Shusta, 2008). 
 
3.2.2 Permeability 
 
Transcellular permeability to small molecule tracers can also yield valuable information 
regarding barrier integrity (Calabria and Shusta, 2008). Most tracers are labelled 
dye or isotope that helps the quantification of the molecule. 
example, is a marker of transendothelial permeability and it has been observed in endothelial 
vesicles (Abbott, 2000; Deli et al.
restrictive BBB accompanies a variety of CNS afflictions, including inflammation, infection, 
ischemia, seizures, and trauma (de Boer and Gaillard, 2006; Song
Fig. 1.12 – Schematic representation of an astrocyte/endothelial cell co
an Model of the Blood-Brain Barrier
 
indicator of paracellular ion flux 
 et al., 2006). There are several methods used in TEER 
voltage-ohm meter (EVOMX) and the 
a computer to monitor TEER 
 et al., 2009). 
 et al., 2006). In BMVEC monocultures 
 
Albumin (a 67
, 2005). Elevated permeability of the normally highly 
 et al., 2007).
-culture system. 
 
STX2 electrode  
TEER is often 
by a fluorescent 
kDa protein), for 
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molecules is less stringent than the BBB 
poorly penetrate across BBB 
static model (Santaguida et al.
 
Fig. 1.13 – Schematic representation of the 
electrodes. 
 
3.2.3 Intercellular junctions
 
The main features of the 
strictly limit the diffusion of blood
been performed regarding these junctions. The most recent of these focus on the relation between 
β-catenin expression and Down
disorganization of ZO-1 during hypoxia (Lu
on TJ and cell adhesion of BMVEC (An and Xue, 2009)
of occludin and claudin-5 during 
depletion of intercellular junctions at the site of bacteria
2009). 
 
3.2.4 Transport across the BBB
 
Membrane transporters and vesicular mechanisms 
from toxic substances and allowing the entrance of others which are necessary
-Brain Barrier
r in vivo and permeability to polar 
in vivo, allowing compounds that would normally 
in vivo to readily diffuse across the endothelial monolayer in the 
, 2006). 
 
transendothelial electrical resistance measur
 
BBB are the presence of tight intercellular junctions which 
-borne solutes and cells into the brain. Several studies have 
’s syndrome in a mouse model (Vorbrodt
 et al., 2009), the ischemic preconditioning effects 
, the caveolae-mediated in
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recent studies regarding this barrier include the regulation of major efflux transporters under 
inflammatory conditions (von Wedel-Parlow et al., 2009), differential expression and function of 
ABC transporters during development and ageing (Bojanic et al., 2009) and their regulation by 
cytokines (Poller et al., 2009). Also, related to ABC transporters, comparative gene expression 
profiles have been done in BMVEC and brain in five species including the human one (Warren 
et al., 2009). 
 
 
4. Aim of the thesis 
 
The main goal of this project was to implement a model of the BBB, relying on the use of 
confluent monolayers of HBMVEC. The procedure should maintain the in vivo barrier 
characteristics and serve as a robust in vitro cell culture tool for research programs addressing 
the BBB in a human model. Given the limited availability of human tissue samples, it will also 
be evaluated whether cells can be stored as frozen stocks without phenotypic drift, which shall 
constitute a remarkable benefit to research studies in the area. In order to further improve the 
exploitation of a single cell culture, it will be further ascertained the number of passages in 
culture with no loss of BMVEC phenotype. 
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Chapter 2 – Materials and Methods 
 
 
1. Chemicals 
 
Collagen type I and endothelial cell growth supplement (ECGS) were acquired from BD 
Biosciences (Bedford, MA, USA); DPX mountant for microscopy was obtained from BDH 
Prolabo (Poole, UK); Hank’s Balanced Salt Solution (HBSS) and glutamax were purchased from 
Invitrogen (Carlsbad, CA, USA); Dulbecco’s modified Eagle medium/nutrient mixture  
F-12 Ham (DMEM-F12), fetal bovine serum (FBS) and heparin were obtained from Biochrom 
(Berlin, Germany); Triton X-100 was obtained from Roche Diagnostics (Germany); antibiotic- 
-antimycotic solution (AB/AM), bovine serum albumin (BSA), Hoechst dye 33258, 
hydrocortisone (HC) and Trypsin-EDTA solution (0.05% Trypsin, 0.02% EDTA in Hank’s 
Balanced Salt Solution) were acquired from SIGMA (St Louis, MO, USA). Other chemicals 
were of analytical grade and were purchased from Sigma or Merck (Darmstadt, Germany). 
Mouse anti-α-SMA was purchased from ABD Serotec (Oxford, UK). Rabbit anti-caveolin-1 
was acquired from Cell Signaling (Danvers, MA, USA). Mouse anti-VE-cadherin and rabbit 
anti-vWF were purchased from Chemicon (Billerica, MA, USA). Rabbit anti-β-catenin, mouse 
anti-claudin-5, rabbit anti-occludin and rabbit anti-ZO-1 were obtained from Invitrogen 
(Carlsbad, CA, USA). Rabbit anti-GLUT-1 was purchased from Santa Cruz Biotechnology (CA, 
USA). Secondary antibodies goat anti-rabbit cyanine dye (CY)2 and goat anti-mouse CY3 were 
acquired from GE Healthcare (Chalfont St. Giles, UK). 
 
2. HBMVEC isolation and culture procedure 
 
Cells were isolated and cultured according to the technique developed by Bernas et al, 
(2009) (Fig. 2.1). Human samples (5-10 mm
3
) of temporal lobe were obtained as discarded tissue 
during operative treatment for epilepsy, after informed consent and approval by the Ethics 
Comission of the Hospital Santa Maria, Lisbon. This technique was also applied to Wistar rats 
(cortex from both hemispheres). The brain sample was transported in a dry tube at room 
temperature to the laboratory, in up to 15 minutes. The sample was placed in a Petri dish 
containing ~5 ml of isolation medium (10 ml FBS, 1 ml Glutamax, 1 ml AB/AM, 88 ml DMEM-
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F12) and the meninges and visible larger vessels were carefully removed under a 
stereomicroscope (Zeiss, model Stemi DV4; Jena, Germany). The tissue was fragmented using 
repeatedly sterile pipettes of 25, 10 and 5 ml, until the sample could be passed easily back and 
forth through the 5 ml pipette. The resulting tissue fragments were filtered thought a series of 
polyester meshes with pore-sizes of 500 µm and 30 µm. The collected fragments were 
transferred in medium to a centrifuge tube and spin at 400 rpm (~30 g) for 10 min. The resulting 
pellet was resuspended in 1 ml isolation supplemented medium (ISM) [10 ml FBS, 1 ml 
Glutamax, 1 ml AB/AM, 2 ml ECGS (50µg/ml), 3.4 ml heparin (1 mg/ml) and 82.6 ml DMEM-
F12]. The suspension was transferred to a T-25 flask previously coated with 2.5 ml collagen type 
I solution (50 µg/ml of collagen in 0.02 N acetic acid), shaking to ensure coverage of the flask, 
and placed to adsorb for 1 hour in incubator. Afterwards, 3 ml of ISM were carefully added to 
the bottom of the T-25 flask without shaking. The flask was incubated at 37 ºC with 5% O2 
(Heraeus, model Function line). Three to four days later the medium was changed for the first 
time and afterwards once a week. Cells were monitored under contrast phase microscopy 
(Olympus optical microscope with phase-contrast equipment, model CK2-TR and Nikon digital 
camera, model L1; Japan). 
  
3. HBMVEC passage 
 
At confluence (approximately 1x 10
6 
cells) , ISM was removed from the T-25 flask and a 
wash was performed with 2 ml versene solution (8.00 g NaCl, 0.40 g KCl, 0.20 g EDTA, 0.02 g 
phenol red in 1 l H20 and adjusted pH to 7.4). 2 ml trypsin-EDTA solution were added and the 
flask placed for 10 minutes in incubator. DMEM/Ham’s F12 + 10 % FBS (37ºC) was added to 
the flask (3 x trypsin volume). All fluid containing cells was harvested to a 50 ml tube and 
centrifuged at 800 rpm (~130 g) for 10 min. After decanting-off the fluid, the pellet was 
resuspended in ISM. The suspension was plated 4 ml per T-25 flask and 500 µl per 12 mm glass 
cover slip previously coated with 2.5 ml or 0.2 ml collagen type I solution, respectively. 
 
4. HBMVEC cryopreservation 
 
Following trypsinization, cells were resuspended in 1 ml ISM. After cell count, equal 
volumes of cell suspension (maximum of 1x 10
6 
cells) and freezing medium [200 µl FBS (20%), 
Establishment and Characterization of a Human Model of the Blood-Brain Barrier 
 
27 
 
10 µl Glutamax, 10 µl AB/AM, 20 µl ECGS (50µg/ml), 34 µl heparin (1 mg/ml), 526 µl 
DMEM-F12 and 200 µl dimethylsulphoxide] were placed in a  cold cryotube. Cryotubes where 
then placed in cryo freezing container from NALGENE (Rochester, NY, USA). After 4 h to 
overnight at -80 ºC, cryotubes were transferred to liquid nitrogen for 30 days. Following this 
time period, cells were thawed at 37 ºC and harvested to a Falcon tube. Up to a maximum of  
4 ml of thawing medium [2 ml FBS (20%), 100 µl Glutamax, 100 µl AB/AM, 200 µl ECGS 
(50µg/ml), 340 µl heparin (1 mg/ml), 7.26 ml DMEM-F12] was added to the suspension and all 
fluid was transferred to a T-25 flask previously coated with 2.5 ml collagen solution and placed 
in incubator at 37 ºC with 5% CO2. 
  
 
Fig. 2.1 – Representative steps of the isolation and culture of human brain microvascular endothelial cells.  
(A) Brain sample placed in a 100 mm dish containing isolation medium; (B) removal of meninges and large vessels 
using sterilized surgical forceps and a stereomicroscope to facilitate the visualization; (C) fragmentation of the tissue by 
repeatedly sterile pipettes of 25 and 10 ml until (D) the sample can be passed effortlessly back and forth through a 5 ml 
pipette; (E) passage of the sample through a 500 µm polyester screen for removal of large fragments; (F) filtration of the 
collected fluid through a 30 µm polyester screen placed over a wire frame for support; (G) collection of the fragments 
retained on the screen by washing into a new dish; (H) pellet of fragments following centrifugation; (I) resuspended 
microvessels and introduction in a collagen coated T-25 flask. 
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5. TEER assessment 
 
To assess TEER, rat BMVEC were grown on Millicell polycarbonate 0.4 µm culture 
plate insert 12 mm diameter for attachment-dependent cell culture acquired from Millipore 
(Billerica, MA, USA). HBMVEC (either fresh or cryopreserved) were grown either on Millicell 
hydrophilic polytetrafluoroethylene (PTFE) or on Millicell polycarbonate 0.4 µm culture plate 
insert 12 mm diameter for attachment-dependent cell culture acquired from Millipore (Billerica, 
MA, USA). TEER was measured firstly after 2 days in vitro (DIV) and daily from then on, using 
the epithelial voltage-ohm meter (EVOMX) and STX2 Electrode (Fig. 1.12), both purchased 
from World Precision Instruments, INC (Hertfordshire, UK). 
 
6. Immunofluorescence 
 
Immunofluorescence was performed both on fresh and cryopreserved HBMVEC, when 
confluence was reached. Supernatant was removed and cells were fixated with  
4% paraformaldehyde in phosphate buffered saline (PBS) for 20 minutes at room temperature. 
Percentage of triton X-100 in permeabilization solution and incubation time varied according to 
primary antibody, as well as whether cells were from cell line or primary cultures (Table 2.1). 
For all antibodies, 3% BSA in PBS was used as blocking for 1 h at room temperature. Cells were 
incubated overnight at 4ºC with the relevant primary antibody (for antibodies dilution, see  
Table 2.1). Secondary antibodies were incubated at room temperature for 1 h (Table 2.1). Both 
primary and secondary antibodies were diluted in blocking solution. Nuclei were stained with 
Hoescht dye 33258 in PBS (1:1000) for 2 minutes. DPX was used as mountant medium. 
Coverslips were observed under upright microscope fitted with widefield epi-fluorescence 
(Zeiss, model Scope.A1) with integrated digital camera (Leica, model DFC490). In order to have 
negative controls, some coverslips were incubated only with secondary antibody. This assured us 
that the signal obtained for coverslips incubated with both primary and secondary antibodies was 
a result of the expression of the target proteins. 
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Table 2.1 – Immunofluorescence permeabilization conditions and antibodies dilution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: α-SMA – α-smooth muscle actin; GLUT-1 – glucose transporter-1; HBMVEC - human brain microvascular endothelial cells; P-gp 
– P-glycoprotein; VE-cadherin – vascular endothelial-cadherin; vWF – von Willebrand factor; ZO-1 – zonula occludens-1. 
 
Target Protein 
Primary Antibody 
Secondary antibody 
HBMVEC line HBMVEC primary culture 
Permeabilization 
dilution 
Permeabilization 
dilution antibody dilution 
Triton (%) Time (min) Triton (%) Time (min) 
ACTA2 0.2 3 1:1000 0.2 3 1:1000 CY3 1:1000 
β-catenin 0.2 3 1:100 0.2 3 1:100 CY2 1:1000 
Caveolin 1 0.2 3 1:100 0.2 3 1:100 CY2 1:1000 
Claudin-5 0.2 15 1:100 0.2 3 1:100 CY3 1:1000 
vWF 0.2 3 1:100 0.2 3 1:100 CY2 1:1000 
GLUT-1 0.2 3 1:100 0.2 3 1:100 CY2 1:1000 
Occludin 0.2 15 1:100 0.2 3 1:100 CY2 1:1000 
P-gp 0.2 3 1:100 0.2 3 1:20 CY3 1:1000 
VE-cadherin 0.5 15 1:10 - - - CY3 1:1000 
ZO-1 0.5 15 1:100 0.2 3 1:100 CY2 1:1000 
2
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Chapter 3 – Results 
 
1. Cell culture implementation 
 
 
It was a very hard working and time-consuming process to implement a primary culture 
of HBMVEC. We have originally adopted the isolation protocol reported by (Liu et al., 2002). 
This uses complicated methods such as Percoll gradients and 3D gels, which require not only 
expensive means and available time, but also expertise. After several tries and failures, as well as 
attempts to contact the authors of the previously referred paper, we established contact with  
Dr. Michael Bernas (University of Tucson, Arizona), who was very helpful in implementing a 
new, simplified and less time-consuming protocol. As human brain tissue is very difficult to 
obtain we have initially used Wistar rat whole brain to implement the protocol. The results here 
presented both for rat and human cells were all originated using the protocol developed under the 
collaboration with Dr. Bernas. 
 
2. Cell culture characterization 
 
2.1. Morphological analysis of rat and human BMVEC by contrast phase microscopy 
 
A week after the day of the isolation procedure, the first resulting cells were visible under 
contrast phase microscopy. Early BMVEC were spindle shaped and with random growth 
direction (Fig. 3.1 A). At the end of 30 DIV, however, these cells were apposed to each other and 
formed monolayers (Fig. 3.1 B). HBMVEC, on their hand, took at least a fortnight to be visible 
under contrast phase microscopy. In resemblance to rat BMVEC, these cells presented random 
growth direction. It appeared as though they were multiplying from within agglomerates formed 
at cell seeding during culture procedure (Fig. 3.1 C). Within 30 DIV, confluence was achieved 
and cells formed a monolayer, though with different morphology. Under contrast phase 
microscopy, confluence HBMVEC appeared hexagonal-like (Fig. 3.1 D). 
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Fig. 3.1 – BMVEC primary cultures from Wistar rat at (A) 8 days and (B) 30 days, and from human brain tissue at 
(C) 14 days and (D) 30 days, under contrast phase microscopy. Original magnification: 100 x. 
 
 
 
2.2. TEER and ZO-1 expression in rat and human BMVEC cultures
 
To better mimic barrier properties, the number of DIV 
studies should be performed was determined. Rat BMVEC 
onto polycarbonate inserts previously coated with collagen type I solution. TEER was measured 
daily from 2 to 11 DIV and compared to control (insert with both
no cells) (Fig. 3.2). TEER increased continuously through time, assuming mostly values around 
100 Ω.cm
2
 and over, with no thresholds. Therefore, further studies were needed.
Rat BMVEC at P1 were grown on collagen coated glass
TEER measurements. Immunostaining for ZO
DIV, 9 DIV, 11 DIV, 16 DIV and 20 DIV (Fig. 3.3). A larger number of cells were visible after 
7 DIV, achieving its maximum at 11 DIV. 
evolving to a lesser number of cells per field at 20 DIV. These cells, however, did not express 
ZO-1 properly in the plasma membrane contour
an Model of the Blood-Brain Barrier
 
after trypsinization 
at cell passage 1 (
 collagen coating and ISM, and 
 coverslips with ISM, parallel to 
-1 was performed on these cells after 2 DIV, 7 
After 16 DIV cells showed spaces between them, 
. 
 
 
 
in which 
P1) were seeded 
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The result of 104 Ω.cm
following days. This might be due to a 
under average, whilst BMVEC TEER is in frame with the remaining results.
 
 
Fig. 3.2 – Daily transendothelial electrical resistance (TEER) 
(BMVEC) in primary culture at cell passage 1, 
Absolute values for BMVEC and control (i
for BMVEC and control. 
 
 
-Brain Barrier
2
 at 4 DIV is out of frame with those obtain
misreading in control, once in Figure
 
measuring for rat brain microvascular endothelial cells 
with isolation supplemented medium (ISM) 
nsert with ISM and no BMVEC). (B) Difference between TEER values 
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ed for previous and 
 3.2 A this result is 
 
 
after 2 days in vitro. (A) 
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Fig. 3.3 – Immunofluorescence microscopy of rat 
culture at cell passage 1, for zonula occudens
(E) 16 DIV and (F) 20 DIV with isolation supplemented medium
 
There are studies which claim that, after cells achieve confluence, the addition of HC to 
growth medium increases expression of TJ proteins and, therefore, enhance barrier properties 
(Förster et al., 2008). So, after 11 DIV, rat BMVEC on both inserts and glass coverslips were 
incubated another 5 DIV with i) ISM, ii) ISM without ECGS, iii) ISM without ECGS a
HC, and the resulting TEER measurements were compared to control (Fig. 3.4). After 1 DIV 
cells had similar TEER values in spite of the different mediums, even though those without 
ECGS in medium composition 
became more evident after 2 and 3 DIV, with ISM with HC reporting the highest values of 291 
Ω.cm
2
 (50 Ω.cm
2
 over ISM without ECGS and 132 
decreased, dropping to less than 100 
 
an Model of the Blood-Brain Barrier
 
brain microvascular endothelial cells (BMVEC) in
-1 after (A) 2 days in vitro (DIV), (B) 7 DIV, (C) 9 DIV, (D) 11 DIV,  
. Original magnification: 630 x.
(either with or without HC) showed a slig
Ω.cm
2
 over ISM). After 4
Ω.cm
2
 at the end of 5 DIV. 
 
 
 primary 
 
nd with 
ht increase. This 
 DIV TEER values 
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Fig. 3.4 – Daily transendothelial electrical resistance (TEER)
(BMVEC) in primary culture at cell passage 1, 
BMVEC with isolation supplemented medium (ISM),
supplement (ECGS), BMVEC with ISM without ECGS and with hydrocortisone (HC), 
and no BMVEC). (B) Difference between TEER values for BMVEC and co
 
To confirm the enhancement of barrier properties, rat BMVEC grown in parallel on glass 
coverslips were stained for ZO
not express ZO-1 in the plasma membrane and showed spaces between the
removed from medium after 11 DIV
were closer apposed to each other, enhancing barrier properties. As for the addition of HC to 
medium, there was no expression for ZO
 
-Brain Barrier
 measuring for rat brain microvascular endothelial cells 
with different media (after 11 days in vitro
 BMVEC with ISM without endothelial cell growth 
and control (insert with 
ntrol for each medium.
-1 (Fig. 3.5). With ISM, as in previous results (Fig. 3.3), cells did 
, not only was ZO-1 expressed at TJ site, as well as BMVEC 
-1 and the majority of cells had died.
 
35 
 
). (A) Absolute values for 
ISM 
 
m. When ECGS was 
 
Establishment and Characterization of a Hum
 
36 
 
 
Fig. 3.5 – Immunofluorescence microscopy of rat 
culture for ZO-1, after 11 days in vitro
and (B) 5DIV with ISM; (C) 3 DIV and (D) 5 DIV with ISM without 
and (F) 5 DIV with ISM with hydrocortisone
 
 Given the above mentioned results, we then proceeded to HBMVEC
TEER measurements were performed on PTFE inserts with collagen coating and with ISM. We 
have chosen to perform TEER measurements for HBMVEC in these inserts as once these are 
clear, it would allow to also monitor cell expansion under contra
showed maximum values of around 15 
and control) at 3 DIV (Fig. 3.6 A,B), quickly dropping afterwards to results similar to those 
measured for control (coated inserts with no cell
of seeding, cells were apposed to each other in resemblance to monolayer. However, just after 
4 DIV, a larger number of cells had died and detached from the insert surface (Fig. 3.6 C,D). 
an Model of the Blood-Brain Barrier
brain microvascular endothelial cells (BMVEC) in
 (DIV) with isolation supplemented medium (ISM) followed by (A) 3 DIV 
endothelial cell growth supplement;
. Original magnification: 630 x. 
 (at P1)
st phase microscopy. Studies 
Ω.cm
2
 (difference between TEER values for HBMVEC 
s). Under contrast phase microscopy, at the time 
 
 
 primary 
 (E) 3 DIV 
 studies. First 
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Fig. 3.6 – Daily transendothelial electrical resistance (TEER) measuring for human brain microvascular endothelial cells 
(HBMVEC) in primary culture after 2 days
supplemented medium and no HBMVEC). (B) Difference between TEER values for HBMVEC and control. HBMVEC 
primary culture under contrast phase microscopy on the day of seeding on the inserts is represented in C and 4 days later 
in D. Original magnification: 100 x. 
 
 New TEER measurements 
different membrane composition (polycarbonate) (Fig. 3.7), used previously in rat BMVEC 
TEER measurements. TEER increased gradually ranging from a minimum of 
time of seeding to 94 Ω.cm
2
whether HBMVEC barrier properties resembled those in rat BMVEC, ECGS was removed from 
medium for 2 DIV for both inserts and coverslips. TEER was measured daily and HBMVEC on 
coverslips were stained for ZO
both mediums, maintaining the same values as on the previous days. 
showed that with regular ISM and at the time of threshold, HBMVEC were apposed to each 
other, presented a hexagonal
boundaries (Fig. 3.8 A). On the other hand, those with the same medium and more DIV, though 
expressing ZO-1 at TJ sites, showed larger spaces between cells (Fig. 3.8 B)
enlarge when removing ECGS from medium (Fig. 3.8 C). Therefore and according with these 
results, to better mimic barrier properties, we have worked with 8 DIV cells after seeding with 
ISM. 
-Brain Barrier
 in vitro. (A) Absolute values for HBMVEC and control (insert with isolation 
were then taken regarding another type of inserts, with 
 after 6 DIV, reaching a threshold from herein on. To evaluate 
-1. Unlike rat BMVEC, TEER for HBMVEC did not increase for 
Immunofluorescence results 
-like shape and expressed ZO-1 at all TJ sites, delimiting cell 
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 at the 
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Fig. 3.7 – Daily transendothelial electrical resistance (TEER)
cells (HBMVEC) in primary culture cell passage 1, after 2 
and control [insert with isolation supplemented medium
values for HBMVEC and control. (C) Absolute values for HBMVEC 
HBMVEC) incubated for 2 DIV with either ISM or ISM 
(D) Difference between TEER values for HBMVEC and control when incubated with either ISM or ISM without 
ECGS, following 9 DIV with ISM in B.
 
Fig. 3.8 – Immunofluorescence microscopy of 
Staining for zonula occludens-1 (ZO-1)
 2 DIV with isolation supplemented medium
without ECGS. Original magnification: 630 x.
 
an Model of the Blood-Brain Barrier
 measuring for human brain microvascular endothelial 
days in vitro (DIV). (A) Absolute values for HBMVEC 
 (ISM) and no HBMVEC]. (B) Difference between TEER 
and control (insert with ISM and no 
without ECGS, following 9 DIV with ISM in A. 
 
human brain microvascular endothelial cells in
 after 9 days in vitro (DIV). (B) Staining for ZO-1 after 9 DIV followed by
 (ISM). (C) Staining for ZO-1 after 9 DIV followed by 2 DIV with ISM 
 
 
 
 
 
 primary culture. (A) 
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2.3. Immunofluorescence analysis of purity and phenotype of HBMVEC cultures
  
To characterize HBMVEC primary culture, cells were stained for sp
GLUT-1 and vWF, and for pericytes marker 
1 and vWF, with little contamination from pericytes (Fig. 3.9). 
selected fields revealed that only 3
 
 
Fig. 3.9 – Characterization of human brain microvascular endothelial cells 
microscopy for (A) glucose transporter
actin (α-SMA). In (C) it is shown in red a pericyte
the culture purity, the total number of nuclei, as well as the number of cells positive for 
counted in 50 randomly selected fields (D).
 
As stated earlier, human samples are difficult to 
optimization process for immuno
laboratory. To determine barrier properties, cells were stained for TJ proteins ZO
claudin-5. AJ components β-catenin and VE
molecules caveolin-1 and P-gp (Fig. 3.10). Immunofluorescence conditions were optimized for 
ZO-1, β-catenin, caveolin-1, occludin and P
Figure 3.10 F. Only after the addition of calcium to the antibody solution fine lines were visible 
-Brain Barrier
α-SMA. At P1, HBMVEC highly expressed GLUT
In fact, analysis of 50 randomly 
% of the cells stained for α-SMA. 
primary culture. Immunofluorescence 
-1 and (B, C) double staining for von Willebrand factor
 with positive staining for α-SMA. For quantitative eva
vWF
 Original magnification: 630 x. 
obtain. Bearing this into account, 
fluorescence analysis was on a HBMVEC line available in the 
-cadherin were also determined, as well as transport 
-gp. Results for VE-cadherin are represented in 
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ecific EC markers 
-
 
 and α-smooth muscle 
luation of 
 and for α-SMA, was 
the 
-1, occludin and 
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delimiting the cells. Several variations were made during optimization for claudin
of Triton X-100 and time of exposure to the permeabilizing solutio
solution, and incubation time with both primary and secondary antibodies. However, in spite of 
all the variations applied we were unable to obtain proper staining for this protein
Therefore, we have discarded these
 
 
an Model of the Blood-Brain Barrier
n, composition of blocking 
 two proteins from HBMVEC characterization.
Fig. 3.10 – Immunofluorescence 
microscopy of human brain microvascular 
endothelial cell line for (A) 
occludens-1, (B) β-catenin, (C) caveol
(D) occludin, (E) P-glicoprotein, 
(F) vascular endothelial-cadherin
claudin-5. Original magnification: 630 x.
 
-5: percentage 
 (Fig. 3.10 G). 
 
 
zonula 
in-1, 
 
 and (G) 
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 When applying immunofluorescence results to primary HBMVEC, our results showed 
that in P1 (Fig. 3.11) these cells expressed both ZO
β-catenin at TJ and AJ sites, respectively, and perfectly delimiting cell boundaries and 
connecting neighbouring cells. Caveolin
by these cells. Occludin, in spite of several attempts of optimization, was not fo
HBMVEC contour but disperse in the cytoplasm.
 
 
 
  
-Brain Barrier
-1 (as already shown in 
-1 was also highly expressed. P-gp was also expressed 
 
Fig. 3.11 – Immunofluorescence
of human brain microvascular endothelial 
cells primary culture for (A) 
occludens-1, (B) β-catenin, (C) caveolin
(D) occludin and (E) P-glicop
magnification: 630 x. 
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3. Evaluation of TEER and phenotype in HBMVEC along passages
 
To characterize the cell passages
were observed under contrast phase microscopy to determine cell morphology. These were also 
stained for specific EC markers
determine cell contamination. To evaluate barrier properties, TEER was assessed and
of ZO-1, β-catenin, caveolin-1 and P
 
3.1. Cell passage 2 (P2) 
 
At P2, HBMVEC under contrast phase microscopy showed no apparent difference in 
morphology from cells at P1, with hexagonal
Immunofluorescence results showed expression for both GLUT
strong decrease in total cell number and with a few spac
contamination from pericytes as only 5
fields (Fig. 3.12). 
 
Fig. 3.12 – Characterization of human brain microvascular endothelial cells primary culture
microscopy and immunofluorescence microscopy for (B) glucose transporter
factor and α-smooth muscle actin (α-SMA)
quantitative evaluation of the culture purity, the total number of nuclei, as well as the number
and for α-SMA, was counted in 50 randomly selected fields (D). Original magnification: 630 x.
an Model of the Blood-Brain Barrier
 following P1, HBMVEC derived from 
 GLUT-1 and vWF, and for the pericytes marker 
-gp determined by immunofluorescence. 
-like shape and forming m
-1 and vWF, though with a 
es in between cells. Still, there was little 
% of the cells stained for α-SMA, in 50 randomly selected 
 at P2
-1 and (C) double staining for 
. In (C) it is shown in red a pericyte with positive staining for α
 of cells positive for 
 
 
 
primary cultures 
α-SMA to 
 expression 
onolayers. 
 
 by (A) contrast phase 
von Willebrand 
-SMA. For 
vWF 
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TEER assessment results for P2 (Fig. 3.13) were very similar to those in P1. 
TEER increased gradually ranging from a minimum of 
maximum of 98 Ω.cm
2
 after 7 DIV. As for immunofluorescence assay (Fig. 3.14), our results 
showed that HBMVEC also express
delimiting cell boundaries and connecting neighbouring cells. Even though not as highly as in 
P1, both caveolin-1and P-gp were expressed in these cells.
 
 
 
Fig. 3.13 – Daily transendothelial elec
(HBMVEC) primary culture at P2, after 2 days 
isolation supplemented medium and no HBMVEC). (B) Difference bet
 
-Brain Barrier
53 Ω.cm
2
 at the time of seeding to a 
 both ZO-1 and β-catenin at TJ and AJ sites, respectively, 
 
tric resistance (TEER) measuring for human brain microvascular endothelial cells 
in vitro. (A) Absolute values for HBMVEC and control (insert with 
ween TEER values for HBMVEC and control.
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Fig. 3.14 – Immunofluorescence microscopy of 
for (A) zonula occludens-1, (B) β-catenin, (C) caveolin
 
 
3.2. Cell passage 3 (P3) 
 
Following the third trypsinization, HBMVEC began to show differences in morphology 
from P1 and P2 under contrast phase microscopy. Most cells were still hexagonal
and did form monolayers. Nevertheless, a large number of endothelial cells with 
sickled-like morphology and not apposed to each other
showed expression for both GLUT
selected fields which is similar to the previous passage (351 cells). Con
was of 7% (Fig. 3.15). 
 
an Model of the Blood-Brain Barrier
human brain microvascular endothelial cells
-1 and  (D) P-glicoprotein. Original magnification: 630 x.
 were visible. Immunofluorescence results 
-1 and vWF. There were in total 377 cells in 50 randomly 
tamination by pericytes 
 
 
 primary culture at P2 
 
-like shaped 
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Fig. 3.15 – Characterization of human brain microvascular endothelial cells primary culture
microscopy and immunofluorescence microscopy for (B) glucose transporter
factor and α-smooth muscle actin (α-
quantitative evaluation of the culture purity, the total number of nuclei, as well as the number of cells p
and for α-SMA, was counted in 50 randomly selected fields (D). Original magnification: 630 
 
 
TEER assessment results for P3 (Fig. 3.16) revealed lower values than in previous 
passages. TEER increased gradually from a minimum of 
maximum of 78 Ω.cm
2
 after 7 DIV. This result is 20
TEER measurement also decreased approximately 20
to those obtained for previous passages
ZO-1 and β-catenin still remained in TJ and AJ sites delimiting cell boundaries of neighbouring 
cells. However, it was visible the presence of few spaces between some of the cells. Caveolin
and P-gp seemed to have not suffered notorious differences in expression.
 
-Brain Barrier
 
-1 and (C) double staining for 
SMA). In (C) it is shown in red a pericyte with positive staining for α
x.
28 Ω.cm
2
 at the time of seeding to a 
 Ω.cm
2
 less than P1 and P2, 
 Ω.cm
2
. Therefore, this result is still similar 
. Our immunofluorescence results (Fig. 3.17) showed that 
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at P2 by (A) contrast phase 
von Willebrand 
-SMA. For 
ositive for vWF 
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Fig. 3.16 – Daily transendothelial electric resistance (
cells (HBMVEC) primary culture at P3. (A) Absolute values for HBMVEC and control (insert with 
supplemented medium and no HBMVEC). (B) Difference between TEER values for HBMVEC and control.
 
Fig. 3.17 – Immunofluorescence microscopy of 
for (A) zonula occludens-1, (B) β-catenin, (C) caveolin
an Model of the Blood-Brain Barrier
TEER) measuring for human brain microvascular endothelial 
human brain microvascular endothelial cells
-1 and  (D) P-glicoprotein. Original magnification: 630 x.
 
 
isolation 
 
 
 primary culture at P3 
 
Establishment and Characterization of a Human Model of the Blood
 
 
3.3. Cell passage 4 (P4) 
 
Under contrast phase microscopy, HBMVEC were in its majority sickled
further separated from each other. Immunofluorescence results showed expression of GLUT
and a decrease in expression of vWF. Total number of cells was of 301, of which 3
positive for α-SMA, resulting in a contamination by pericytes of 13
 
Fig. 3.18 – Characterization of human brain microvascular endothelial cells primary culture
microscopy and immunofluorescence microscopy
factor and α-smooth muscle actin (α-
quantitative evaluation of the culture purity, the total number o
and for α-SMA, was counted in 50 randomly selected fields (D). Original magnification: 630 x
 
For P4, TEER slowly increased from a minimum of 
maximum of 52 Ω.cm
2
 after 9 DIV (Fig. 3.19).  In P3 this value was reached at the end of 
4 DIV. Immunofluorescence revealed that ZO
β-catenin (Fig. 3.20). Caveolin
 
-Brain Barrier
% (Fig. 3.18).
 
 for (B) glucose transporter-1 and (C) double staining for 
SMA). In (C) it is shown in red a pericyte with positive staining for α
f nuclei, as well as the number of cells positive for 
23 Ω.cm
2
 at the time of seeding to a 
-1 expression underwent a larger decrease than 
-1 and P-gp had also decreased their expression.
 
47 
-like shaped and 
-1 
8 were 
 
 
at P2 by (A) contrast phase 
von Willebrand 
-SMA. For 
vWF 
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Fig. 3.19 – Daily transendothelial electric resistance (
cells (HBMVEC) primary culture P4, after 2 
with isolation supplemented medium and no HBMVEC). (B) Difference between TEER values for HBMVEC and 
control. 
 
Fig. 3.20 – Immunofluorescence microscopy of 
(A) zonula occludens-1, (B) β-catenin, (C) caveolin
an Model of the Blood-Brain Barrier
TEER) measuring for human brain microvascular endothelial 
days in vitro. (A) Absolute values for HBMVEC and control (insert 
human brain microvascular endothelial primary culture 
-1 and  (D) P-glicopreotein. Original magnification: 630 x.
 
 
 
at P4 for  
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3.4. Cell passage 5 (P5) 
 
HBMVEC in P5 appeared to grow in random directions and further separate from one 
another, under contrast phase microscopy
cells decreased to 227 of which 
pericytes of 17% (Fig. 3.21). 
 
Fig. 3.21 – Characterization of human brain microvascular endothelial cells primary culture
microscopy and immunofluorescence microscopy for (B) glucose transporter
factor and α-smooth muscle actin (α-
quantitative evaluation of the culture p
and for α-SMA, was counted in 50 randomly selected fields (D). Original magnification: 630 x
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Fig. 3.22 – Daily transendothelial electric resistance (
cells (HBMVEC) primary culture P5, after 2 
with isolation supplemented medium and no HBMVEC). (B) Difference between TEER values for HBMVEC and 
control. 
 
Fig. 3.23 – Immunofluorescence microscopy 
(A) zonula occludens-1, (B) β-catenin, (C) caveolin
an Model of the Blood-Brain Barrier
TEER) measuring for human brain microvascular endothelial 
days in vitro. (A) Absolute values for HBMVEC and control (insert 
of human brain microvascular endothelial cells 
-1 and (D) P-glicoprotein. Original magnification: 630 x.
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4. HBMVEC cryopreservation 
 
 Following trypsinization, HBMVEC were cryopreserved at -80 ºC. After 30 days, cells 
were thawed and seeded onto a collagen coated T-25 flask. Given that human brain samples are 
difficult to obtain, as stated before in this thesis, all cryopreserved cells were used in 
immunofluorescence studies once the small amount of cells obtained did not allow us to perform 
both immunofluorescence and TEER measurements. As cells were thawed at P1, this passage 
could only be characterized by its morphology under contrast phase microscopy.  Confluence 
was achieved 15 DIV after seeding (Fig. 3.24). As previous to cryopreservation, HBMVEC were 
closely apposed to each other forming a monolayer. Nonetheless, most cells were not  
hexagonal-like shaped as in comparison to P1 before cryopreservation, but more elongated. 
 
  
Fig.3.24 – Contrast phase microscopy from human brain microvascular endothelial cells primary culture 
cryopreserved for 30 days in liquid nitrogen at -80 ºC. Confluence was achieved 15 days after thawing. Original 
magnification: 100 x.  
 
4.1. Morphological analysis of cryopreserved HBMVEC by contrast phase microscopy 
 
Following trypsinization, HBMVEC at P2 under contrast phase microscopy showed 
differences in morphology from P1 cells. EC did form monolayers, but their shape had evolved 
more sickled-like. P3 cryopreserved HBMVEC were very similar to P2. P4 and P5 
cryopreserved HBMVEC appeared to have large breaches between them (Fig. 3.25). 
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Fig.3.25 – Contrast phase microscopy
cryopreserved for 30 days in liquid nitrogen at 
magnification: 100 x. 
 
 
 
4.2. Immunofluorescence analysis of purity of HBMVEC cultures
 
Cryopreserved cells at P2 had little contamination from pericytes as only 2
α-SMA. There was still little contamination from pericytes at P3 given that 
positive for α-SMA, representing 4
the same as in non-cryopreserved cells at P3, with 7
appeared at P5 as 37 out of 354 cells stained for pericytes marker. This meant a 
10% contamination with cells other than HBMVEC.
an Model of the Blood-Brain Barrier
 from human brain microvascular endothelial cells
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Fig. 3.26 – For  quantitative evaluation of the culture purity, the total number of nuclei, as well as the number of cells 
positive for von Willebrand factor and for α-smooth muscle actin, was counted in 50 randomly selected fields (D). 
Original magnification: 630 x. 
 
 
4.3. Immunofluorescence analysis of phenotype of HBMVEC cultures after 
cryopreservation 
 
To determine the phenotype of cryopreserved HBMVEC, cells were stained for 
endothelial cell marker vWF, TJ protein ZO-1, AJ component β-catenin, vesicular transport 
protein caveolin-1 and ABC transporter P-gp. Immunofluorescence results showed strong 
expression for vWF at P2, slightly decreasing for HBMVEC at P3. At the stage of P4, vWF 
signal was weaker, rapidly decreasing to P5 where it was extremely dim. P2 cryopreserved 
HBMVEC expressed ZO-1 around all cell limits at TJ site with a very strong signal. Along the 
passages, there seemed to be a decrease in ZO-1 expression mainly after P4, though cell contours 
were still visible. As for β-catenin, it was expressed at P2 though only at few AJ sites, whilst P3 
appeared to have slightly increased its expression. At P4 and P5 β-catenin presented several 
breaches in signal. As for caveolin-1, it presented very high signal both at P2 and P3. It seemed 
to weaken its expression after P4, though it might be related to the spaces in between cells. When 
it comes to P-gp, opposing the previous proteins, it seemed to maintain its expression along cell 
passages (Fig. 3.27). 
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Fig. 3.27 – Immunofluorescence microscopy of 
and P5. Immunostaining for: endothelial cell marker 
occludens (ZO)-1, adherens junctions 
ATP-binding cassette transporter P-glicoprotein (
an Model of the Blood-Brain Barrier
human brain microvascular endothelial cells primary culture
von Willebrand Factor (vWF), tight junction
component β-catenin, vesicular transport protein 
P-gp). Original magnification: 630 x. 
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Chapter 4 – Discussion 
 
 
The discovery of the BBB has allowed several studies focused on its properties 
throughout the last decades. These may be performed under a large variety of study models, 
either in vivo, ex vivo, in silico or in vitro. However, these lack important characteristics. They 
require more means than those at hand, like in vivo studies (Malina et al., 2009), and apply to 
few circumstances, such as in silico prediction methods which are mainly used for permeability 
studies (Mensch et al., 2009). In vitro studies permit to mimic the BBB microenvironment 
studying a larger range of properties and functions (Aschner et al., 2006). The majority of these 
studies fall upon brain tissue from rat (Perrière et al., 2007), mouse (Coisne et al., 2005), feline 
(Fletcher et al., 2009), porcine (Zhang et al., 2006) and bovine (Zhang et al., 2009) models. 
Therefore, the results obtained must take into account the differences between species. The better 
alternative would be to work directly with human tissue. However, the existing methods are both 
time-consuming and expensive (Hewett, 2009). 
Given these facts, we have developed a method for HBMVEC isolation which requires 
lesser equipment and can be done in little over 2 hours. We have studied the barrier properties 
through cell passages. Moreover, to circumvent the difficulty to obtain human samples, we have 
carried out cryopreservation studies. 
It is known that EC properties are determined by their location in the organism (Hayashi 
et al., 1997; Craig et al., 1998). Primary cultures of rat BMVEC isolated by methods reported in 
literature are spindle shaped, apposed and form monolayers (Dux et al., 1991; Hiu et al., 2008; 
Vajda et al., 2008). Primary HBMEVC, in resemblance to the previous cells, also present 
themselves in monolayers and juxtaposed (Jain et al., 2006; Wong et al., 2007), but with 
different morphology. With our method, we were able to obtain juxtaposed monolayered cell 
cultures for both species. Furthermore, we were able to evidence that the morphology of rat and 
human EC was specific and relative to its species. 
TEER is usually over 100 Ω.cm
2
 (Calabria and Shusta, 2008). We have been able to 
assess rat TEER measurements of over 150 Ω.cm
2
 with our cells. This result is slightly above the 
expected, and there is no threshold. This might be due to the fact that measurements were taken 
up at 11 DIV because corresponding immunofluorescence showed that cells did not reach 
confluence before that period of time. 
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  It has been stated that TEER measurements could be further improved by adding HC 
and removing ECGS to the medium used in the inserts (Calabria et al., 2006). In line with this, 
we verified that 2 days after such procedure, TEER assumed a difference of 100 Ω.cm
2
 over the 
original results. Nonetheless, shortly after, cells lost their barrier properties and eventually died. 
HC affected differently cells isolated with our method in comparison to others, probably needing 
the use of a more diluted solution. This experiment has allowed us to understand that rat 
BMVEC TJ expression could be enhanced, and therefore barrier properties, by removing ECGS 
from the growth medium ISM. ECGS contains a large number of growth factors, and these seem 
to have to be removed from medium for cells to express TJ proteins properly. 
When assessing TEER in HBMVEC, after an initial value of little over 15 Ω.cm
2
 at  
2 DIV, TEER would suddenly decrease to results very similar to those in control. BMVEC are 
usually seeded with a concentration of nearly 1 x 10
5
 cells per cm
2 
(Inglis et al., 2004; Nakagawa 
et al., 2009).  To rule out the hypothesis of low initial cell concentration, cells were seeded at a 
concentration of 8.5 x 10
4
 cells per cm
2
 onto the insert. As seen is Figure 3.6, after 4 DIV most 
cells had died and detached from the insert surface. This may be a result of the inserts 
themselves. The inserts used in this experiment were clear PTFE inserts and therefore with 
different membrane composition from those used in rat BMVEC TEER assessment 
(polycarbonate). In our experience, HBMVEC had a greater difficulty both to attach to the 
surface of the insert and to form a proper monolayer. 
New TEER assessment was performed with equal inserts to those used with rat BMVEC, 
this time with results around 100 Ω.cm
2
 as expected (Calabria and Shusta, 2008). Unlike what 
was determined for rat BMVEC, when removing ECGS from medium HBMVEC grew further 
apart from each other. Besides growth factors in its composition, ECGS is also effective in cell 
attachment and proliferation, what might explain the need of its presence in the medium for 
HBMVEC to better express TJ. Therefore, immunofluorescence results indicate that with our 
method we have been able to isolate EC expressing TJ protein ZO-1 with no need to remove 
ECGS and consequently with enhanced barrier properties. 
To confirm the endothelial phenotype, specific EC markers were assessed, such as vWF 
and GLUT-1 (Craig et al., 1998; Shimizu et al., 2008), and to determine the degree of 
contamination, also the pericyte marker α-SMA (Lai and Kuo, 2005). Our results indicate that 
with our method 97% of the cells in culture are EC. This reflects a highly pure culture. 
To validate the HBMVEC monolayer as a reliable BBB model, proteins specific to TJ 
(ZO-1, occludin and claudin-5) and AJ (β-catenin) were determined, alongside with cellular 
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vesicular transport machinery marker caveolin-1 and the ABC transporter P-gp. Given that cell 
lines are an easier method to access HBMVEC (Tai et al., 2009), we have used optimized 
immunofluorescence for these proteins on a human cell line available in our lab. It was expected 
that the cell line would express caveolin-1 and P-gp on the inner surface (Smith and Gumbleton, 
2006), and ZO-1, occludin, claudin-5 and β-catenin in the plasma membrane along the peripheral 
cell limits (Vorbrodt and Dobrogowska, 2003; Vorbrodt et al., 2009). With our 
immunofluorescence protocol we have seen some breaches in signal for all proteins. For both 
claudin-5 and VE-cadherin, there was little signal. However Western blot assay confirmed that 
all proteins are expressed in these cells (data not shown). Therefore, it is possible that the 
optimal conditions for immunofluorescence detection of claudin-5 and VE-cadherin were still 
not achieved. The available HBMVEC line does not exhibit growth inhibition by cell-cell 
contact, and consequently neither does it form monolayer. Thus, the poor expression of these 
proteins may also be related to these characteristics.  
Primary cultures’ characteristics are different in each isolation but still present more 
primary endothelial traits than cell lines (Bouis et al., 2001). With our isolation method primary 
HBMVEC expressed ZO-1 and β-catenin in the plasma membrane across the peripheral cell 
limits. Whereas in cell line the signal for these proteins had breaches, in the primary culture the 
signal delimited the entire cell contour and were noticeable cell-cell interactions. Furthermore, 
HBMVEC also expressed P-gp on the cell’s inner surface, as well as caveolin-1. This protein is 
also expressed as microdomains in the cytoplasm, working as cellular vesicular transport 
machinery (Huber et al., 2001). As for the lack of signal for occludin in the cell contour, this 
might be due to internalization via a caveolae-dependent pathway. A recent study showed that 
during TJ remodelling of the BMVEC, occludin and claudin-5 might be internalized becoming 
sorted into recycling endosomes until a new signal causes their return to the cell membrane to re-
establish junctional interactions (Stamatovic et al., 2009). Further tests, as Western blot assay, 
need to be performed in order to determine whether our primary HBMVEC express this protein 
or if further immunofluorescence optimization is required. 
To better evaluate the relevance and innovation of the implementation of our method, we 
have studied HBMVEC through cell passages. Several tests presented a contamination by 
pericytes of nearly 8% (Wagner et al., 2003). There are studies described which involve the use 
of puromycin to decrease such contamination (Calabria et al., 2006). However, extreme caution 
with puromycin’s concentration is required as this may be toxic to cell (Perrière et al., 2005). 
With our method, culture cell purity varies from 97% to 83%. P1, P2 and P3 are considered to be 
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pure cultures with only 2%, 5% and 7%, respectively, of contamination by pericytes. P4 and P5 
have contaminations over 10%, showing that pericytes’ growth is favoured after each 
trypsinization. Given these facts, we have been able to implement an isolation method that 
results in highly pure cultures without the need of using puromycin. 
For primary cultures, TEER measurements were expected to be of approximately  
100 Ω.cm
2
 (Calabria and Shusta, 2008).
 
For our primary cultures, the first three passages had 
high TEER with results very similar to that in literature, though for P3 TEER values were lower. 
This behaviour was similar in both contrast phase microscopy and immunofluorescence results 
for all proteins. The difference between the number of total cells in P1, P2 and P3 might be due 
to a loss of cells during trypsinization. Therefore with our isolation method we have been able to 
implement a model which could be used not only in P1 but also in P2, maintaining cells 
phenotype. Moreover, if we take into account both that trypsin digests the proteins that facilitate 
adhesion to the container and the results obtained for P3, by using a gentler substitute 
(TrypLE
TM
) this cell passage might also be used. However, further studies are needed. 
There are studies that claim that the expression of caveolin-1 increases with BBB 
breakdown, and at the same time decreases the expression of both occludin and claudin-5  
(Nag et al., 2007). This could explain the fact that even though barrier properties such as TEER 
and TJ breakdown along cell passages, we have not noticed a decrease in caveolin-1 expression. 
As it was previously referred in this work, obtaining a reliable supply of human brain 
tissue is an extremely difficult task. With the article on primary porcine BMVEC cryopreserved 
for up to 12 months (Smith et al., 2007), came the idea that the same might be achieved for 
primary HBMVEC. With the original protocol, cells were stored at -80 ºC and, when thawing, 
centrifuged to remove DMSO. This however reflected in no cellular growth after plating. The 
problem in focus may have been caused by the freezing temperature for the time required, as 
well as for a bigger sensibility to centrifuge whilst thawing. To attempt to solve it, cells were 
stored at -80 ºC in isopranol overnight and transferred to liquid nitrogen for 30 days. When 
thawing cells were immediately seeded onto a collagen coated T-25 flask. Medium was replaced 
the following day to remove remaining DMSO. After a fortnight, cells had reached confluence 
and under contrast phase microscopy resembled non-cryopreserved primary HBMVEC. After 
trypsinization, cryopreserved P2 had only 2% contamination by pericytes in a total of 854 cells, 
which reflect a pure culture. The immunofluorescence obtained for ZO-1, β-catenin, caveolin-1 
and P-gp, was very similar to that obtained in P2 non-cryopreserved HBMVEC. Passages P3 and 
P4 were pure with 4% and 7% of contamination by pericytes, though P4 showed breaches in 
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signal for the studied proteins. The morphological differences that cryopreserved HBMVEC had 
from cells that had not undergone cryopreservation, might be due to long exposure to extremely 
low temperature. A bigger susceptibility to trypsin could also be an effective cause, which might 
be solved in further studies with a trypsin substitute. As for the decrease in expression of vWF, 
there are studies that corroborate our results. According to Craig et al. (1998), vWF staining has 
many variables: the higher the passage numbers the more cells stained faintly, and cells which 
had been recently trypsinized were negative for this factor. 
Even still, we have been able to successfully cryopreserve primary HBMVEC and 
recover those 30 days later with high culture purity and expressing TJ and AJ proteins, as well as 
vesicular transport machinery and ABC transporters. 
 
With this work we have been able to implement a new method to isolate and culture 
primary HBMVEC, which comprises important barrier properties such as high TEER, presence 
of TJ and AJ, as well as vesicular transport machinery and at least one ABC transporter. We 
have then established a new simplified human model of the BBB, which maintains its phenotype 
and barrier properties up to P2. Furthermore, we have successfully cryopreserved primary 
HBMVEC maintaining the expression of proteins important to barrier properties. The 
availability of cryopreserved primary HBMVEC that can be recovered when required will 
therefore be of significant benefit to researchers. 
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Chapter 5 – Future perspectives 
 
The success of the implementation of our method has inspired us to continue studying the 
BBB properties even further. In future studies we aim to elucidate the role of microglia in the 
neurovascular unit, namely the conditions determining protective or injurious effects of 
microglia, upon stimulation, on the BBB. An in vitro model of human BBB, composed by 
double (microglia + endothelial cells) and triple co-cultures (plus astrocytes or pericytes), will be 
implemented to assess if microglia influence structure and properties of the BBB and whether 
microglia reactivity is modulated by the presence of other neurovascular unit components. In rats 
acutely and chronically injected with lipopolysaccharide we will assess the patterns of microglial 
activation, as well as of BBB disruption. Additionally, we will use several compounds known to 
modulate microglial reactivity, in both in vitro and in vivo models, to evaluate their influence on 
the tightness of BBB integrity. Understanding the microglia-mediated signalling processes that 
regulate BBB properties shall provide new targets for potential CNS medicines to acute or 
chronic neuroinflammation. This work shall constitute the PhD thesis entitled “Has microglia a 
role in blood-brain barrier function and dysfunction?” which shall hopefully start in January 
2010, provided that FCT supports the submitted PhD grant proposal SFRH/BD/62959/2009. To 
a better accomplishment of the proposed project we count with the valuable collaboration of 
Maria Deli, who implemented a triple co-culture system (Nakagawa et al., 2009), through a 
training in her lab. 
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